PLoS ONE (Jan 2014)

Twisted gastrulation, a BMP antagonist, exacerbates podocyte injury.

  • Sachiko Yamada,
  • Jin Nakamura,
  • Misako Asada,
  • Masayuki Takase,
  • Taiji Matsusaka,
  • Taku Iguchi,
  • Ryo Yamada,
  • Mari Tanaka,
  • Atsuko Y Higashi,
  • Tomohiko Okuda,
  • Nariaki Asada,
  • Atsushi Fukatsu,
  • Hiroshi Kawachi,
  • Daniel Graf,
  • Eri Muso,
  • Toru Kita,
  • Takeshi Kimura,
  • Ira Pastan,
  • Aris N Economides,
  • Motoko Yanagita

DOI
https://doi.org/10.1371/journal.pone.0089135
Journal volume & issue
Vol. 9, no. 2
p. e89135

Abstract

Read online

Podocyte injury is the first step in the progression of glomerulosclerosis. Previous studies have demonstrated the beneficial effect of bone morphogenetic protein 7 (Bmp7) in podocyte injury and the existence of native Bmp signaling in podocytes. Local activity of Bmp7 is controlled by cell-type specific Bmp antagonists, which inhibit the binding of Bmp7 to its receptors. Here we show that the product of Twisted gastrulation (Twsg1), a Bmp antagonist, is the central negative regulator of Bmp function in podocytes and that Twsg1 null mice are resistant to podocyte injury. Twsg1 was the most abundant Bmp antagonist in murine cultured podocytes. The administration of Bmp induced podocyte differentiation through Smad signaling, whereas the simultaneous administration of Twsg1 antagonized the effect. The administration of Bmp also inhibited podocyte proliferation, whereas simultaneous administration of Twsg1 antagonized the effect. Twsg1 was expressed in the glomerular parietal cells (PECs) and distal nephron of the healthy kidney, and additionally in damaged glomerular cells in a murine model of podocyte injury. Twsg1 null mice exhibited milder hypoalbuminemia and hyperlipidemia, and milder histological changes while maintaining the expression of podocyte markers during podocyte injury model. Taken together, our results show that Twsg1 plays a critical role in the modulation of protective action of Bmp7 on podocytes, and that inhibition of Twsg1 is a promising means of development of novel treatment for podocyte injury.